Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, ...
Researchers from China Pharmaceutical University reported the discovery and preclinical characterization of allosteric inhibitors of Src homology-2-containing protein tyrosine phosphatase 2 (SHP2) as ...
Tyrosine-protein phosphatase non-receptor type 1 (PTP1B) acts as a negative regulator of the insulin signaling pathway by dephosphorylating both the insulin receptor (IR) and the insulin receptor ...
those given placebo. Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose symptoms included fall risk and cognitive issues ...
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision allosteric therapeutics. The collaboration will utilize Atavistik's ...
来自MSN11 个月
Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase ...The dosing of patients with advanced sarcoma and Merkel cell carcinoma by intravenous infusion of Curadev's systemic allosteric STING agonist, CRD3874-SI, has been initiated in a Phase 1a/b dose ...
Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果